Literature DB >> 9114048

Ultrarapid, highly efficient viral gene transfer to the heart.

J K Donahue1, K Kikkawa, D C Johns, E Marban, J H Lawrence.   

Abstract

Gene therapy for common myocardial diseases will require effective and homogeneous gene delivery throughout the intact heart. We created two experimental models to identify and optimize parameters important for adenovirus-mediated cardiac gene transfer. In cultured rabbit ventricular myocytes, the percentage of infected cells increased with higher absolute numbers of virus particles, longer durations of virus exposure, physiological temperatures, and specific culture media compositions. Simulating the in vitro conditions, we delivered adenovirus to intact rabbit hearts by intracoronary perfusion. The percentage of infected cells increased with higher coronary flow rates, longer virus exposure times, and higher virus concentrations. Under optimal conditions, nearly 100% of myocytes expressed the reporter gene beta-galactosidase after ex vivo infection. This novel delivery method, the first to demonstrate virtually complete transduction of any intact organ, could be adapted to achieve widespread gene transfer in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114048      PMCID: PMC20781          DOI: 10.1073/pnas.94.9.4664

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  Techniques for perfusing isolated rat hearts.

Authors:  J R Neely; M J Rovetto
Journal:  Methods Enzymol       Date:  1975       Impact factor: 1.600

2.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: a prototype for gene therapy for disorders of cardiac excitability and contractility.

Authors:  H B Nuss; D C Johns; S Kääb; G F Tomaselli; D Kass; J H Lawrence; E Marban
Journal:  Gene Ther       Date:  1996-10       Impact factor: 5.250

4.  Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors.

Authors:  J Mühlhauser; M Jones; I Yamada; C Cirielli; P Lemarchand; T R Gloe; B Bewig; S Signoretti; R G Crystal; M C Capogrossi
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

5.  Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus.

Authors:  E Barr; J Carroll; A M Kalynych; S K Tripathy; K Kozarsky; J M Wilson; J M Leiden
Journal:  Gene Ther       Date:  1994-01       Impact factor: 5.250

6.  Manipulation of adenovirus vectors.

Authors:  F L Graham; L Prevec
Journal:  Methods Mol Biol       Date:  1991

7.  Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy.

Authors:  K L March; J E Madison; B C Trapnell
Journal:  Hum Gene Ther       Date:  1995-01       Impact factor: 5.695

8.  Highly efficient gene transfer into adult ventricular myocytes by recombinant adenovirus.

Authors:  L A Kirshenbaum; W R MacLellan; W Mazur; B A French; M D Schneider
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

9.  Efficient gene transfer into myocardium by direct injection of adenovirus vectors.

Authors:  R J Guzman; P Lemarchand; R G Crystal; S E Epstein; T Finkel
Journal:  Circ Res       Date:  1993-12       Impact factor: 17.367

10.  Dependence of hypoxic cellular calcium loading on Na(+)-Ca2+ exchange.

Authors:  M C Haigney; H Miyata; E G Lakatta; M D Stern; H S Silverman
Journal:  Circ Res       Date:  1992-09       Impact factor: 17.367

View more
  35 in total

1.  Cardiomyocytes induce endothelial cells to trans-differentiate into cardiac muscle: implications for myocardium regeneration.

Authors:  G Condorelli; U Borello; L De Angelis; M Latronico; D Sirabella; M Coletta; R Galli; G Balconi; A Follenzi; G Frati; M G Cusella De Angelis; L Gioglio; S Amuchastegui; L Adorini; L Naldini; A Vescovi; E Dejana; G Cossu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

Review 2.  Targeting calcium cycling proteins in heart failure through gene transfer.

Authors:  Federica del Monte; Roger J Hajjar
Journal:  J Physiol       Date:  2003-01-01       Impact factor: 5.182

Review 3.  Defining the success of cardiac gene therapy: how can nuclear imaging contribute?

Authors:  Norbert Avril; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-23       Impact factor: 9.236

Review 4.  Delivery of gene and cellular therapies for heart disease.

Authors:  Justin A Mariani; David M Kaye
Journal:  J Cardiovasc Transl Res       Date:  2010-05-11       Impact factor: 4.132

Review 5.  Cardiac gene therapy.

Authors:  Antoine H Chaanine; Jill Kalman; Roger J Hajjar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

Review 6.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

Review 7.  Percutaneous approaches for efficient cardiac gene delivery.

Authors:  Kiyotake Ishikawa; Jaume Aguero; Charbel Naim; Kenneth Fish; Roger J Hajjar
Journal:  J Cardiovasc Transl Res       Date:  2013-06-08       Impact factor: 4.132

Review 8.  Gene therapy in heart failure.

Authors:  Leif Erik Vinge; Philip W Raake; Walter J Koch
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

Review 9.  Cardiac gene therapy: optimization of gene delivery techniques in vivo.

Authors:  Michael G Katz; JaBaris D Swain; Jennifer D White; David Low; Hansell Stedman; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

10.  Gene therapy approaches to ventricular tachyarrhythmias.

Authors:  J Kevin Donahue; Tetsuo Sasano; Kamilla Kelemen
Journal:  J Electrocardiol       Date:  2007 Nov-Dec       Impact factor: 1.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.